Top Page
Aroa Biosurgery Ltd
(Sydney:ARX)
Aroa Biosurgery Ltd (ARX) vs. iShares MSCI Australia ETF (EWA)
Aroa Biosurgery Ltd Business Overview & Revenue Model
Aroa Biosurgery Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 82.36M | 76.97M | 63.36M | 59.31M | 36.88M | 20.51M |
| Gross Profit | 70.39M | 65.99M | 54.10M | 50.06M | 28.17M | 14.25M |
| EBITDA | 5.06M | 2.65M | -6.78M | 683.92K | -3.75M | -7.05M |
| Net Income | -1.66M | -3.47M | -9.75M | -370.68K | -7.79M | -17.63M |
Balance Sheet | ||||||
| Total Assets | 95.27M | 98.94M | 101.88M | 109.07M | 104.71M | 73.12M |
| Cash, Cash Equivalents and Short-Term Investments | 20.71M | 20.13M | 27.73M | 43.00M | 53.35M | 33.93M |
| Total Debt | 6.14M | 5.83M | 6.82M | 6.65M | 5.46M | 14.90M |
| Total Liabilities | 14.34M | 14.35M | 14.79M | 13.69M | 11.30M | 19.43M |
| Stockholders Equity | 80.93M | 84.59M | 87.08M | 95.38M | 93.40M | 53.69M |
Cash Flow | ||||||
| Free Cash Flow | 4.60M | -5.69M | -10.00M | -10.66M | -15.39M | -6.05M |
| Operating Cash Flow | 5.73M | -2.33M | -6.76M | -3.53M | -10.86M | -4.68M |
| Investing Cash Flow | -10.79M | 273.54K | 9.31M | 6.79M | -32.41M | -19.74M |
| Financing Cash Flow | -1.83M | -1.34M | -948.41K | -471.78K | 34.98M | 34.06M |
Aroa Biosurgery Ltd Technical Analysis
Aroa Biosurgery Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$17.45B | 44.90 | 20.11% | 1.64% | 4.32% | 9.24% | |
54 Neutral | AU$842.83M | 63.87 | 16.49% | ― | 23.31% | 151.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$108.36M | -8.07 | -31.98% | ― | 34.20% | -23.90% | |
49 Neutral | AU$260.50M | -157.29 | -2.01% | ― | 16.93% | 76.47% | |
47 Neutral | AU$2.30B | -60.51 | -44.49% | ― | 55.91% | 22.60% | |
44 Neutral | AU$167.29M | -15.69 | -70.55% | ― | ― | -257.32% |
Aroa Biosurgery Ltd Corporate Events
Aroa Biosurgery Limited, a medtech firm specialising in biosurgical and regenerative tissue products for surgical and wound care applications, is listed on the Australian Securities Exchange under the code ARX. The company has announced the cessation of 6,753 ARXAAK options, which lapsed on 19 October 2025 after conditions attached to the rights were not satisfied, resulting in a small reduction of potential dilutive securities on issue but no change to the existing ordinary share capital.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery has welcomed a decision by the US Centers for Medicare & Medicaid Services that ensures its Symphony wound-care products will remain available for outpatient treatment of diabetic foot ulcers and venous leg ulcers under Medicare at least through the end of 2026. CMS has introduced a three-tier classification for skin substitute products—covered, discretionary and non-covered—with Symphony placed in the discretionary category, allowing Medicare Administrative Contractors to reimburse it on a case-by-case basis while additional clinical data are gathered. Aroa has already completed a randomized controlled trial of Symphony, expects publication in 2026, and intends to submit the findings to Medicare contractors ahead of a year-end 2026 review that will underpin future coverage decisions, a process the company views as validating its clinical strategy and supporting continued access for US patients and clinicians.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd released its half-year results for 2026, highlighting its commitment to advancing regenerative healing technologies. The company continues to focus on enhancing its market position by developing innovative medical products, although specific financial details and impacts on stakeholders were not disclosed in the release.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited reported a 14% increase in total revenue for the first half of FY26, reaching NZ$44.9 million, with significant growth in its Myriad product line. The company achieved a normalized EBITDA profit of NZ$1.8 million, a significant improvement from a loss in the previous year, and ended the period with a positive net cash flow. Aroa also received relief from quarterly reporting requirements by the ASX, indicating a stable financial position and operational efficiency. The company reaffirmed its FY26 guidance, projecting continued revenue growth and improved EBITDA, signaling a positive outlook for stakeholders.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd reported a significant improvement in its financial performance for the six months ending 30 September 2025. The company achieved a 14% increase in product sales and a 259% rise in project fees, contributing to a 64% reduction in loss before tax from ordinary activities. This financial progress underscores Aroa’s strengthened market position and operational efficiency, which could positively impact stakeholders and enhance its competitive edge in the medical technology industry.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced the issuance of unquoted equity securities, including 519,444 restricted stock units and 888,888 performance rights, as part of an employee incentive scheme. This move is likely aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning positively.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited is hosting an investor event on November 25, 2025, to discuss its H1 FY26 financial results and commercial outlook. The event will feature presentations from Aroa’s leadership, commercial partner TelaBio, and surgeons discussing clinical outcomes using Aroa’s Myriad™ product. This gathering aims to provide investors with insights into Aroa’s product innovation, clinical efficacy, and growth trajectory, potentially influencing stakeholder perspectives and the company’s market positioning.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced the cessation of John Pinion as a director, effective October 31, 2025. This update includes details of his interests in the company’s securities, which consist of fully paid ordinary shares and options. The announcement is part of the company’s compliance with ASX listing rules and may have implications for its governance and strategic direction.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited has announced the appointment of Paul Shearer as a Non-Executive Director, bringing his extensive experience in the medical device industry to the company. Shearer’s global commercial expertise, particularly in the United States, is expected to bolster Aroa’s growth strategy as it continues to expand its market presence. Concurrently, John Pinion will retire from the Board after a decade of service, during which he contributed significantly to the company’s milestones. This leadership transition is poised to enhance Aroa’s strategic oversight and operational execution, potentially impacting its industry positioning and stakeholder interests.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has released its Q2 quarterly cashflow report, emphasizing its commitment to advancing regenerative healing technologies. The announcement, while not a prospectus or an offer of securities, serves to educate investors about the company’s financial performance and strategic direction. This release could impact the company’s market positioning by highlighting its ongoing efforts in innovation and product development, potentially influencing stakeholder perceptions and investment decisions.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited reported positive financial performance for the quarter ending September 2025, with a net cash flow of NZ$2.1 million and cash receipts of NZ$23.5 million. The company achieved its highest sales quarter for the Myriad product line and published eight new peer-reviewed studies, enhancing its clinical credibility. A proposed US reimbursement policy change could benefit Aroa’s Symphony product, potentially improving its market positioning. The company plans to release its H1 FY26 results in November and will host an investor event in Sydney.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.